Elanco Animal Health Incorporated (NYSE:ELAN) Receives $28.55 Average Target Price from Brokerages

Elanco Animal Health Incorporated (NYSE:ELAN) has received a consensus rating of “Moderate Buy” from the thirteen research firms that are presently covering the stock, MarketBeat.com reports. One analyst has rated the stock with a sell rating, two have assigned a hold rating, nine have issued a buy rating and one has given a strong buy rating to the company. The average 12-month price objective among brokers that have issued a report on the stock in the last year is $28.5455.

ELAN has been the subject of several analyst reports. Citigroup increased their price target on shares of Elanco Animal Health from $30.00 to $31.00 and gave the company a “buy” rating in a research report on Thursday, May 7th. Piper Sandler reaffirmed an “overweight” rating on shares of Elanco Animal Health in a research note on Monday, June 29th. Weiss Ratings lowered shares of Elanco Animal Health from a “sell (d+)” rating to a “sell (d)” rating in a report on Monday, May 11th. Wall Street Zen cut Elanco Animal Health from a “strong-buy” rating to a “buy” rating in a research note on Sunday, May 24th. Finally, JPMorgan Chase & Co. boosted their price target on Elanco Animal Health from $28.00 to $30.00 and gave the company an “overweight” rating in a report on Thursday, May 7th.

Elanco Animal Health Trading Down 0.4%

NYSE ELAN opened at $25.84 on Tuesday. Elanco Animal Health has a 1-year low of $13.39 and a 1-year high of $27.72. The company has a current ratio of 2.16, a quick ratio of 1.12 and a debt-to-equity ratio of 0.60. The stock has a 50-day moving average of $23.63 and a 200-day moving average of $23.89. The firm has a market cap of $12.91 billion, a PE ratio of -51.68, a price-to-earnings-growth ratio of 1.69 and a beta of 1.68.

Elanco Animal Health (NYSE:ELAN) last posted its quarterly earnings results on Wednesday, May 6th. The company reported $0.40 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.34 by $0.06. Elanco Animal Health had a positive return on equity of 7.42% and a negative net margin of 4.95%.The business had revenue of $1.37 billion for the quarter, compared to analyst estimates of $1.28 billion. During the same period last year, the company earned $0.37 EPS. Elanco Animal Health’s revenue for the quarter was up 14.9% compared to the same quarter last year. Elanco Animal Health has set its Q2 2026 guidance at 0.250-0.285 EPS and its FY 2026 guidance at 1.030-1.090 EPS. As a group, sell-side analysts forecast that Elanco Animal Health will post 1.11 EPS for the current year.

Insider Buying and Selling

In other Elanco Animal Health news, CEO Jeffrey N. Simmons acquired 4,971 shares of the business’s stock in a transaction dated Friday, May 15th. The shares were purchased at an average cost of $20.09 per share, for a total transaction of $99,867.39. Following the transaction, the chief executive officer owned 171,971 shares in the company, valued at $3,454,897.39. This represents a 2.98% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Rajeev A. Modi bought 4,911 shares of Elanco Animal Health stock in a transaction dated Friday, May 15th. The shares were acquired at an average cost of $20.35 per share, for a total transaction of $99,938.85. Following the completion of the purchase, the insider directly owned 160,812 shares of the company’s stock, valued at approximately $3,272,524.20. This trade represents a 3.15% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. 1.14% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the stock. NewEdge Advisors LLC boosted its stake in shares of Elanco Animal Health by 133.7% during the 4th quarter. NewEdge Advisors LLC now owns 1,096 shares of the company’s stock valued at $25,000 after purchasing an additional 627 shares in the last quarter. Root Financial Partners LLC increased its position in shares of Elanco Animal Health by 50.7% during the fourth quarter. Root Financial Partners LLC now owns 1,759 shares of the company’s stock valued at $40,000 after buying an additional 592 shares during the period. Uniplan Investment Counsel Inc. bought a new position in Elanco Animal Health in the fourth quarter worth about $41,000. Torren Management LLC bought a new position in Elanco Animal Health in the fourth quarter worth about $46,000. Finally, Bessemer Group Inc. lifted its holdings in Elanco Animal Health by 33.2% in the first quarter. Bessemer Group Inc. now owns 2,105 shares of the company’s stock worth $50,000 after buying an additional 525 shares during the period. 97.48% of the stock is owned by hedge funds and other institutional investors.

About Elanco Animal Health

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.